Back to Results
First PageMeta Content
Biology / Gardasil / Human papillomavirus / Cervical cancer / Wart / HPV vaccine / Genital wart / Vaginal intraepithelial neoplasia / Pap test / Papillomavirus / Medicine / Microbiology


Merck conducted six phase 1 and phase 2 clinical studies between 1997 and 2004
Add to Reading List

Document Date: 2006-05-17 08:37:35

Open Document

File Size: 394,76 KB

Share Result on Facebook

Company

EGL / Merck Inc. / /

Continent

Asia / Europe / South America / /

Country

United States / /

Event

FDA Phase / /

IndustryTerm

prevention of HPV disease / vaccine product / test triage algorithm / colposcopy algorithm / prevention of cervical cancer / /

MedicalCondition

Cancer / disease / Cervical intraepithelial neoplasia grade / HPV / Cervical cancer / cervical carcinoma / Vulvar Cancer / hepatitis B / HPV infection / genital warts / human papilloma virus / CIN / Vaginal Cancer / infection / HPV disease / adenocarcinoma / /

MedicalTreatment

vaccination / /

Organization

Vaccine and Related Biological Products Advisory Committee / /

Position

investigator / forward for clinical development / /

Product

VRBPAC Background Document Gardasil™ HPV Quadrivalent Vaccine / Quadrivalent Vaccine / AN47906 / VLP vaccine / MITT-3 / Study / Background Document Gardasil™ HPV Quadrivalent Vaccine / VLP / Gardasil™ / HPV / Gardasil / HPV Quadrivalent Vaccine / /

ProvinceOrState

Indiana / /

Region

Latin America / Australia North America / /

Technology

colposcopy algorithm / mandatory Pap test triage algorithm / /

SocialTag